Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing.

Human Gene Therapy
Luk H VandenbergheJames M Wilson

Abstract

Vectors based on adeno-associated virus (AAV) are the subject of increasing interest as research tools and agents for in vivo gene therapy. A current limitation on the technology is the versatile and scalable manufacturing of vector. On the basis of experience with AAV2-based vectors, which remain strongly cell associated, AAV vector particles are commonly harvested from cell lysates, and must be extensively purified for use. We report here that vectors based on other AAV serotypes, including AAV1, AAV8, and AAV9, are found in abundance in, and can be harvested from, the medium of production cultures carried out with or without serum. For AAV2, this difference in compartmentalization is largely due to the affinity of the AAV2 particle for heparin, because an AAV2 variant in which the heparin-binding motif has been ablated gives higher yields and is efficiently released from cells. Vector particles isolated from the culture medium appear to be functionally equivalent to those purified from cell lysates in terms of transduction efficiency in vitro and in vivo, immunogenicity, and tissue tropism. Our findings will directly lead to methods for increasing vector yields and simplifying production processes for AAV vectors, which shou...Continue Reading

References

Jul 27, 2002·Annual Review of Cell and Developmental Biology·Gregory A Smith, Lynn W Enquist
Jul 1, 1964·Journal of Chronic Diseases·D J FINNEY
May 23, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Katsuya InagakiHiroyuki Nakai
Jul 18, 2006·Nature Medicine·Luk H VandenbergheJames M Wilson
Jul 29, 2006·Circulation Research·Christina A PacakBarry J Byrne
Nov 17, 2007·The Journal of Clinical Investigation·Shih-Wen LinHildegund C J Ertl
Apr 29, 2008·The New England Journal of Medicine·Albert M MaguireJean Bennett
Apr 29, 2008·The New England Journal of Medicine·James W B BainbridgeRobin R Ali
Jan 13, 2009·The Journal of Infectious Diseases·Roberto CalcedoJames M Wilson

❮ Previous
Next ❯

Citations

Apr 17, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Pavitra S RamachandranBeverly L Davidson
Apr 15, 2011·Gene Therapy·N Pulicherla, A Asokan
Feb 9, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Casey A MaguireJohan Skog
Feb 6, 2013·PloS One·Luk H VandenbergheJames M Wilson
Jun 17, 2014·Human Gene Therapy Methods·Peter BellJames M Wilson
Sep 23, 2014·Human Gene Therapy·Zachary FitzpatrickCasey A Maguire
Feb 11, 2016·Human Gene Therapy Methods·Matthew J BenskeyFredric P Manfredsson
Feb 26, 2016·Molecular Therapy. Methods & Clinical Development·Taro TomonoTakashi Okada
Oct 18, 2011·Neurobiology of Disease·Thomas B LentzR Jude Samulski
Oct 7, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Joshua C GriegerRichard Jude Samulski
Sep 22, 2015·Scientific Reports·Yuta KohroMakoto Tsuda
Mar 15, 2016·Nature Medicine·Jean-Sébastien JoyalLois E H Smith
Apr 14, 2016·Molecular Therapy. Methods & Clinical Development·Bryan A PirasMichael M Meagher
Jul 25, 2015·Molecular Therapy. Methods & Clinical Development·Gabriella Dias FlorencioRachid Benchaouir
Mar 24, 2015·The Journal of Clinical Investigation·Wenjun XiongConstance L Cepko
May 26, 2016·Molecular Therapy. Methods & Clinical Development·Laura Adamson-SmallNathalie Clément
Nov 30, 2016·Human Gene Therapy·Lisa M KattenhornSamuel C Wadsworth
Feb 9, 2017·Biotechnology Journal·Marc-André RobertBruno Gaillet
Aug 12, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Bence György, Casey A Maguire
Oct 15, 2010·Human Gene Therapy·Xiao Xiao
Jun 25, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ye SunJing Chen
Sep 21, 2019·Scientific Reports·Toyokazu KimuraMarkus Michael Bachschmid
May 4, 2017·The Journal of Experimental Medicine·Ye SunLois E H Smith
Mar 23, 2017·Human Gene Therapy Methods·Maria Schnödt, Hildegard Büning
Jan 8, 2013·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Koichi MiyakeYukihiko Hirai
Mar 6, 2019·Proceedings of the National Academy of Sciences of the United States of America·Wenjun XiongConstance L Cepko
Jul 17, 2020·Molecular Therapy. Methods & Clinical Development·Huiren ZhaoW Hans Meisen
Dec 12, 2018·Molecular Therapy. Methods & Clinical Development·Taro TomonoTakashi Okada
Dec 7, 2020·Journal of Pharmaceutical Sciences·Vibhor GuptaIsmael J Hidalgo
Jul 27, 2021·Current Opinion in Biotechnology·Daniel G BracewellC Mark Smales

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
scraping
electrophoresis
PCR
enzyme-linked immunosorbent assay
flow filtration
flow cytometry
ELISA

Software Mentioned

FlowJo
7500

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.